Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II VAC2.2/VI therapy for newly diagnosed intermediate-risk rhabdomyosarcoma
jRCTs051180207Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Feb 2018
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vincristine, actinomycin D, cyclophosphamide and irinotecan in rhabdomyosarcoma (RMS), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: event-free survival. Started Feb 2018; status: active, not recruiting.
02
Drugs
vincristineactinomycin Dcyclophosphamideirinotecan
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on jRCTs051180207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180207.